Redmile Group, LLC Cytosorbents Corp Transaction History

Redmile Group, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.79 - $4.17 $151,659 - $353,307	-84,726 Reduced 31.81%	181,639 $612,000
Q1 2022 May 16, 2022	SELL	$2.88 - $4.23 $1.3 Million - $1.91 Million	-450,879 Reduced 62.86%	266,365 $850,000
Q4 2021 Feb 14, 2022	SELL	$4.05 - $8.11 $1.33 Million - $2.65 Million	-327,190 Reduced 31.33%	717,244 $3.01 Million
Q3 2021 Nov 15, 2021	SELL	$7.0 - $9.71 $1.82 Million - $2.52 Million	-259,935 Reduced 19.93%	1,044,434 $8.48 Million
Q2 2021 Aug 16, 2021	SELL	$7.55 - $9.42 $6.22 Million - $7.76 Million	-823,262 Reduced 38.69%	1,304,369 $9.85 Million
Q1 2021 May 17, 2021	BUY	$8.23 - $11.48 $604,905 - $843,780	73,500 Added 3.58%	2,127,631 $18.5 Million
Q4 2020 Feb 16, 2021	SELL	$7.65 - $8.98 $359,550 - $422,060	-47,000 Reduced 2.24%	2,054,131 $16.4 Million
Q3 2020 Nov 16, 2020	BUY	$7.37 - $11.54 $15.5 Million - $24.2 Million	2,101,131 New	2,101,131 $16.8 Million

16.7M

15.4K

Ticker CTSO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 43,577,400
Market Cap $42.3M
Description
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunct...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.